摘要
目的:探讨英夫利西治疗重度溃疡性结肠炎(UC)的安全性和有效性.方法:报道2例重度UC治疗中英夫利西的用法、疗效及安全性,并复习近年国内外相关文献.结果:1例患者在接受3次英夫利西5mg/kg诱导缓解后并以相同剂量每8wk1次维持治疗,输注5次后达到黏膜愈合.另1例患者应用英夫利西5mg/kg效果欠佳,加量至10mg/kg后效果明显好转,输注5次后达到黏膜愈合.2例患者均未发生英夫利西相关的副反应.文献复习显示英夫利西可诱导中重度UC的临床缓解,治疗效果衰减的患者增加剂量可重新建立疗效反应.英夫利西有诱发机会性感染等多种副反应的风险,治疗期间应严密监测、积极预防.结论:英夫利西治疗重度UC是安全和可行的,可作为治疗重度UC的选择方案之一.
AIM： To assess the feasibility, safety, and efficacy of infliximab in patients with severe ulcerative colitis （UC）. METHODS： Two patients with severe UC were treated with infliximab. The safety and efficacy of infliximab were evaluated, and relevant literature was reviewed. RESULTS： The first patient underwent induction therapy with infliximab 5 mg/kg at weeks 0, 2 and 6 and maintenance therapy with infliximab every 8 weeks. Complete bowel healing was achieved after five infliximab infusions. The second patient, who initially did not respond to infusions with infliximab 5 mg/kg, was subsequently treated with a higher dose （10 mg/kg） of infliximab. Mucosal healing was achieved after five times of infliximab treatment. No infliximab-associated adverse events occurred in both patients. It has been reported in recent years that infliximab is effective for the induction and maintenance of clinical remission in patients with moderate to severe UC. If attenuation of the response to 5 mg/kg dose occurs, increasing the dose of infliximab can get re-achievement of response. However, serious side effects of infliximab including opportunistic infections were reported, necessitating careful monitoring of therapy. CONCLUSION： Infliximab is safe and effective in patients with severe UC and represents a new useful alternative modality for the treatment of severe UC.
出处
《世界华人消化杂志》
CAS
北大核心
2011年第23期2496-2500,共5页
World Chinese Journal of Digestology
